Pursuing our tradition for the 6th year, MDoutlook is the first disease intelligence organization to publish on the clinical impact of new data released at the annual American Society of Clinical Oncology meeting, held June 1-4, 2013 in Chicago.
Collaborating with our global network of 75,000+ cancer treaters, we have already received more than 300 completed surveys from 23 countries less than 10 days after the meeting. Through four surveys – launched directly following ASCO – we pulse our network of verified and validated physicians to assess the value and impact on daily cancer management of new clinical and research data presented.
Focusing on key new data presented in Thyroid, GastroIntestinal (focus on CRC) and Gynecological Cancers and new immunotherapeutics, we will be distributing the results in 4 reports.
The new clinical data presented has significant clinical impact according to the 96 thyroid cancer experts responding to our OncoPoll. This report has the details and is the first of a series of four to be released in the next few weeks: MDoutlook ASCO OncoPoll 2013 – Thyroid Cancer.
We thank all physicians and other professionals involved for working closely to make this well-received series of reports a reality. We also continue to work with our friends at Oncology Business Review (OBR) to ensure maximum distribution of this report; their Editor’s Blog has a copy of the results.
MDoutlook is disease intelligence redefined:
•Governed by ThoughtLeaders
•Driven by in-house disease experts
•Powered by access to proprietary network of treaters
Our post-ASCO OncoPolls™ have generated responses from more than 2,500 cancer treaters in 44 countries over the last 6 years, with insight delivered within 5 business days from fielding.
If you have any questions or would like to discuss how MDoutlook can support your disease intelligence needs, please contact us directly.